European health regulators have taken a major step toward authorizing a groundbreaking vaccine that protects against both COVID-19 and seasonal influenza in a single shot — a first in the history of respiratory disease immunization. The European Medicines Agency’s (EMA) human medicines committee has formally recommended authorizing Moderna’s combined mRNA COVID-19/flu vaccine, branded mCombriax, paving the way for use across the European Union after final approval by the European Commission.
The development reflects broader advances in mRNA science that have been closely examined by research publications such as Harvard Science Review, which has highlighted the expanding potential of next-generation vaccine platforms.
A Novel Approach to Dual Protection
The vaccine at the heart of this decision, mCombriax (also known by its investigational code, mRNA-1083), is designed to simultaneously stimulate immunity against SARS-CoV-2 and influenza viruses, using messenger RNA technology. This innovative formulation combines the genetic instructions for antigens from both viruses, simplifying what has traditionally been two separate vaccination processes into a single seasonal shot — a major advance in preventive medicine.
According to the EMA, the recommendation targets adults aged 50 and older, a group especially vulnerable to severe outcomes from both influenza and COVID-19. The committee’s favorable opinion is now subject to review by the European Commission, which typically follows the EMA’s guidance and could issue final authorization just a few weeks later.
Why Combination Vaccines Matter
Seasonal respiratory viruses such as influenza and SARS-CoV-2 continue to cause significant illness and strain on health systems each year. Although COVID-19 is no longer officially classified as a global public health emergency, the European Medicines Agency continues to track vaccines and treatments for the disease as part of its regulatory mandate.
Scientific studies have shown that combination vaccines can provide robust immune responses against both diseases, potentially outperforming separate injections, especially in adults over 50. One large trial involving more than 8,000 participants reported that those who received the combined vaccine generated immune responses that were comparable to or stronger than the responses from separate flu and COVID-19 shots.
Public health experts argue that simplifying the vaccination process — particularly for older adults and people with busy lives — can help increase vaccine uptake and reduce the yearly burden of respiratory illness on medical facilities.
Moderna’s Regulatory Journey and Industry Context
Moderna’s journey to this milestone has had its challenges. While the company’s COVID-19 vaccines achieved global success early in the pandemic, demand for standalone vaccines has dwindled as the pandemic phase receded. Meanwhile, regulatory pathways in the United States have been more complex; Moderna briefly withdrew its U.S. application for the combination vaccine to address additional data requirements from the FDA.
Moderna is also pursuing a standalone mRNA influenza vaccine (mRNA-1010), along with other next-generation respiratory vaccines, in global regulatory filings that include the U.S., Canada, and Australia.
What This Means for Europe’s Vaccination Strategy
If final authorization is granted by the European Commission, mCombriax could be deployed in time for the 2026–2027 flu and COVID-19 season in parts of the EU, with broader availability expected as national vaccination campaigns adopt the shot. This would mark a notable shift in how respiratory viral diseases are prevented, especially for older populations at higher risk of complications.
Scientists and policymakers will be watching closely, as the success of combined vaccines could influence future strategies for immunization against a range of pathogens beyond influenza and COVID-19.
